Home » Stocks » CELC

Celcuity Inc. (CELC)

Stock Price: $12.60 USD 0.85 (7.23%)
Updated Jan 15, 2021 4:00 PM EST - Market closed
After-hours: $13.24 +0.64 (5.08%) Jan 15, 4:32 PM
Market Cap 129.74M
Revenue (ttm) n/a
Net Income (ttm) -8.73M
Shares Out 10.27M
EPS (ttm) -0.85
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 15
Last Price $12.60
Previous Close $11.75
Change ($) 0.85
Change (%) 7.23%
Day's Open 11.99
Day's Range 11.73 - 12.86
Day's Volume 7,370
52-Week Range 4.42 - 12.86

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
Accesswire - 3 weeks ago

- UCLA Jonsson Comprehensive Cancer Center and Vanderbilt-Ingram Cancer Center will also participate - Study will evaluate the efficacy and safety of NERLYNX® and FASLODEX® in metastatic HR-po...

Seeking Alpha - 2 months ago

Celcuity Inc. (CELC) CEO Brian Sullivan on Q3 2020 Results - Earnings Call Transcript

Seeking Alpha - 5 months ago

Celcuity Inc. (CELC) CEO Brian Sullivan on Q2 2020 Results - Earnings Call Transcript

Seeking Alpha - 10 months ago

Celcuity Inc. (CELC) CEO Brian Sullivan on Q4 2019 Results - Earnings Call Transcript

Zacks Investment Research - 1 year ago

While domestic economic growth has been benefiting small-cap stocks until now, you should consider selling some of the stocks before entering 2020 because of poor earnings growth projections.

Other stocks mentioned: AAWW, BPFH, RRGB
Seeking Alpha - 1 year ago

Celcuity Inc. (CELC) CEO Brian Sullivan on Q3 2019 Results - Earnings Call Transcript

Zacks Investment Research - 1 year ago

Celcuity, Inc. (CELC) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Zacks Investment Research - 1 year ago

Celcuity, Inc. (CELC) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects.

Seeking Alpha - 1 year ago

Celcuity's (CELC) CEO Brian Sullivan on Q2 2019 Results - Earnings Call Transcript

Zacks Investment Research - 1 year ago

Celcuity, Inc. (CELC) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects.

Zacks Investment Research - 1 year ago

Celcuity, Inc. (CELC) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects.

About CELC

Celcuity, a clinical stage biotechnology company, discovers cancer sub-types and therapeutic options for cancer patients in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the targeted therapy that treats it. It develops CELsignia HSF test to diagnose two new sub-types of HER2-negative breast cancer. The company is also developing CELsignia MP test to diagnose 11 cancer sub-types in breast, lung, colon, ovarian, k... [Read more...]

Industry
Diagnostics & Research
IPO Date
Sep 20, 2017
CEO
Brian F. Sullivan
Employees
27
Stock Exchange
NASDAQ
Ticker Symbol
CELC
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 2 analysts, the average rating for Celcuity stock is "Buy." The 12-month stock price forecast is 16.50, which is an increase of 30.95% from the latest price.

Price Target
$16.50
(30.95% upside)
Analyst Consensus: Buy